TRAW (Traws Pharma) PB Ratio: (As of Jun. 26, 2026)


TRAW Traws Pharma Inc TRAW
49 GF Score
Price $0.85
GF Value $12.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Traws Pharma's share price is $0.8453. Traws Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.52. Hence, Traws Pharma's PB Ratio of today is .

The historical rank and industry rank for Traws Pharma's PB Ratio or its related term are showing as below:

During the past 13 years, Traws Pharma's highest PB Ratio was 49.25. The lowest was 0.40. And the median was 1.69.

TRAW's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Traws Pharma's average Book Value Per Share Growth Rate was -144.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Traws Pharma was 0.70% per year. The lowest was -79.10% per year. And the median was -25.55% per year.

Back to Basics: PB Ratio


Traws Pharma  (NAS:TRAW) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Traws Pharma PB Ratio Related Terms


Traws Pharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Traws Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma PB Ratio Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 0.48 1.47 0.00 0.00

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 1.27 2.90 0.00 0.00

TRAW vs CVM, CRIS, QNCX: PB Ratio Comparison

For the Biotechnology subindustry, Traws Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's PB Ratio falls into.


TRAW
49GF Score
Traws Pharma Inc TRAW
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Traws Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.8453/-0.523
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.85 is trading 93.5% below its estimated GF Value™ of $12.92. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • PB Ratio:
  • GF Value™: $12.92 vs. price of $0.85 (93.5% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
49GF Score

Get the complete analysis for TRAW

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price
$12.92
GF Value